ImmuCell Q2 Net Income Hits $1.8M on Legal Settlement, Plans $8M Capacity Expansion
ICCC has more than doubled off its 52-week low of $4.52.
Summary
ImmuCell reported Q2 revenue of $7.2 million, up 11.5% year-over-year, with net income of $1.84 million ($0.20 EPS) boosted by a one-time $2 million legal settlement from a former contract manufacturer. Gross margin declined due to lower manufacturing volumes, costs from a discontinued development program, and scrap from a quality issue with purchased material. The company plans an $8 million two-phase expansion of First Defense capacity—$3.5 million for freeze-drying (completion expected in H1 2027) and $4.5 million for colostrum processing—aiming to triple capacity and improve product economics over the next 18 months. This follows the preliminary Q2 sales announcement on July 9, adding full income statement details and expansion plans. The legal settlement is non-recurring, so core operating performance was weaker than net income suggests.
At the time of this announcement, ICCC was trading at $10.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.6M. The 52-week trading range was $4.52 to $12.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.